Huagai Capital overview
Huagai Capital contact information
Offices
Room 504-508, 5th Floor, China Resources Building, No. 8 Jianguomen North Street, Dongcheng District, Beijing, , ChinaContacts
| Name | Job title | Location | |
|---|---|---|---|
 Mr. Xun Wang | Job titleChief Investment Officer | LocationBeijing, China | Email  --------- |
| Mr. Eric Tsang | Job titleManaging Partner | LocationBeijing, China | Email ----------- |
| Mr. Yi Zhang | Job titleManaging Partner | LocationBeijing, China | Email ----- |
| Mr. Xiaolin Xu | Job titleFounding Partner and Chairman | LocationBeijing, China | Email ----- |
Huagai Capital funds managed
Closed funds: 3
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----------- | Close dateJan 2022 | Strategy ---------- | |
Fund size ------- | Close dateMay 2021 | Strategy ---------- | |
Fund size --------- | Close dateApr 2020 | Strategy ----- | |
Stories that mention Huagai Capital
How to enter China's secondaries market
China’s booming LP-led market is offset by a nascent GP-led market and challenges unique to international investors.
Secondaries players spy opportunity in China reopening
Speaking at the HKVCA’s annual forum, Colin Sau, managing partner of TR Capital, said the firm is increasing its focus on China in 2023 after a slowdown in recent years.
GenFleet Therapeutics rallies $75m Series C
GenFleet Therapeutics, a clinical-stage biotechnology company with a focus on therapies in oncology and immunology, has raised $75 million in Series C financing.
Asian private equity: Tentative steps forward
Capital is flocking to safer hands as regulatory and geopolitical headwinds threaten market sentiment towards PE in the region.
PAQ Therapeutics scores $30m Series A
PAQ Therapeutics, a biotechnology company, has raised $30 million in Series A financing.
EdiGene snags about $67m Series B
Beijing-based EdiGene, Inc., a developer of genome editing technologies, has raised about $67 million in Series B financing.
Immvira nets $58m Series B
Immvira Group Company, a Chinese developer of new generation oncolytic viruses as potential cancer therapeutics, has raised $58 million in Series B financing.